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Background: Colorectal cancer (CRC) is common and leads to significant morbidity and mortality. Although
screening with fecal occult blood testing (FOBT) or endoscopy has been shown to decrease CRC mortality,
screening rates remain suboptimal. Screening rates are particularly low for people with low incomes and members
of underrepresented minority groups. FOBT should be done annually to detect CRC early and to reduce CRC
mortality, but this often does not occur. This paper describes the design of a multifaceted intervention to increase
long-term adherence to FOBT among poor, predominantly Latino patients, and the design of a randomized
controlled trial (RCT) to test the efficacy of this intervention compared to usual care.
Methods: In this RCT, patients who are due for repeat FOBT are identified in the electronic health record (EHR) and
randomized to receive either usual care or a multifaceted intervention. The usual care group includes multiple
point-of-care interventions (e.g., standing orders, EHR reminders), performance measurement, and financial
incentives to improve CRC screening rates. The intervention augments usual care through mailed CRC screening
test kits, low literacy patient education materials, automated phone and text message reminders, in-person follow
up calls from a CRC Screening Coordinator, and communication of results to patients along with a reminder card
highlighting when the patient is next due for screening. The primary outcome is completion of FOBT within
6 months of becoming due.
Discussion: The main goal of the study is to determine the comparative effectiveness of the intervention
compared to usual care. Additionally, we want to assess whether or not it is possible to achieve high rates of
adherence to CRC screening with annual FOBT, which is necessary for reducing CRC mortality. The intervention
relies on technology that is increasingly widespread and declining in cost, including EHR systems, automated
phone and text messaging, and FOBTs for CRC screening. We took this approach to ensure generalizability and
allow us to rapidly disseminate the intervention through networks of community health centers (CHCs) if the RCT
shows the intervention to be superior to usual care.
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The United States Preventive Services Task Force (USPSTF)
recommends colorectal cancer (CRC) screening using
fecal occult blood test (FOBT), sigmoidoscopy, or colon-
oscopy in adults, beginning at age 50 and continuing until
age 75 [1]. However, rates of CRC screening remain in-
adequate [2,3]. In 2006, only 60.8% of adults 50 or older
reported recent CRC screening [3]. Screening rates are
even lower among Black and Hispanic populations [4-10]
and in areas with higher poverty rates [10].
Community health centers (CHCs) frequently use FOBT
as their only form of CRC screening due to limited access
and high cost of endoscopy. However, FOBT should be
done every 1–2 years to optimize detection of polyps and
early cancer. Performing the test less often may result in
many aggressive cancers being missed until an advanced
stage, markedly reducing the health benefits of population
screening. Individuals in vulnerable groups often face mul-
tiple barriers to annual FOBT screening, including lack of
regular source of care, less frequent routine medical visits,
frequent changes in residence, and lack of awareness of
the need for annual FOBT screening. If FOBT cannot be
conducted annually or biennially with high reliability, it
may be necessary to expand the use of alternative screen-
ing modalities, such as endoscopy (i.e., sigmoidoscopy or
colonoscopy), to reduce CRC mortality. However, there is
currently inadequate financing and an inadequate number
of endoscopists available for CHCs to use endoscopy as a
primary screening modality.
Few studies have examined the rate of repeat CRC
screening with FOBT [11,12]. To our knowledge, none
have been conducted in populations with high preva-
lence of barriers to screening (e.g., low literacy, varied
cultural norms, transportation difficulties). The assump-
tion that FOBT is an effective CRC screening strategy
presumes it will be done at least biennially, and cost-
effectiveness studies of CRC screening strategies have
found that the results are sensitive to the rate of adher-
ence [13]. Therefore, studies are needed to develop and
test strategies to increase adherence to FOBT over mul-
tiple years. It is important to evaluate a) whether these
strategies improve adherence compared to high-quality
usual care, and b) whether multifaceted interventions
can achieve the consistently high adherence rates year
after year that are required to reduce late-stage CRC and
CRC mortality.
This paper describes the design of a comparative
effectiveness study of an intervention to maximize the
number of poor, predominantly Latino patients cared for
at a CHC who complete a repeat FOBT within
six months of becoming due for CRC screening. We first
describe the CHC’s efforts to improve CRC screening
rates prior to the start of this study. We then review crit-
ical aspects of the study design and intervention,including a) the use of an IRB-approved waiver of in-
formed consent to randomize all eligible patients and
achieve a fully representative study population, b) the
conceptual framework for the multifaceted intervention,
c) the outreach tools developed for each component of
the intervention, d) separation of the intervention into
two discrete phases to allow assessment of the marginal
benefit of outreach by a CRC Screening Coordinator
compared to lower-cost outreach strategies, e) the pa-
tient educational tools developed to provide feedback to
patients with negative FOBTs and to improve successful
completion of diagnostic colonoscopy among patients
with positive FOBTs, and f ) the outcome assessment. Fi-
nally, we discuss the significance of the study and some
of the potential implications.
Previous efforts to improve CRC screening rates at Erie
Family Health Center
This study is being conducted at Erie Family Health
Center (EFHC), a federally-qualified health center net-
work in Chicago, Illinois that serves an overwhelmingly
Latino population; 66% are best served in Spanish; 36%
are uninsured; and 91% come from households with in-
comes below the Federal Poverty Line. EFHC uses the
General Electric Centricity electronic health record
(EHR), which is supported by the Alliance of Chicago
Community Health Services. The EHR has clinical re-
minders for chronic disease management and clinical
preventive services and allows EFHC to routinely gather
data for quality of care measures.
In December, 2007, 16% of all eligible patients were up
to date on CRC screening based on USPSTF guidelines.
This rate had been stable over the previous six months and
was similar to many other CHCs in Chicago. Between
December, 2007 and October, 2009, EFHC implemented
several system-level changes designed to improve CRC
screening rates. These efforts are best viewed as a single
quality improvement initiative with multiple components:
a) performance measurement, feedback, and financial in-
centives, b) implementation of a team-based care approach
empowering medical assistants (MAs) to recommend CRC
screening, and c) development of strategies to improve ac-
cess to diagnostic colonoscopy.
Performance measurement, feedback, and financial
incentives
EFHC uses performance measures to determine provider
incentive payments. These measures are chosen every
year by the providers themselves to reflect their prior-
ities, rather than being imposed by EFHC’s management
team. In 2007, providers chose CRC screening as a per-
formance measure. As a result, adult medicine providers
were routinely told what percent of their patient panel
was up to date on CRC screening. Along with their
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their screening rates rank among other adult providers
within the organization. Performance on the CRC meas-
ure was also used to allocate performance-based incen-
tive bonuses. Each quarter, providers receive a bonus for
falling in the top and middle terciles of similar providers
in each measure. Along with their individual performance,
providers are also shown how their screening rates rank
among other adult providers within the organization.
Empowerment of medical assistants to offer CRC screening
if overdue
EFHC also implemented a standing order that allowed
MAs to recommend guaiac card FOBT screening during
pre-appointment triage and vital signs measurement to
patients who were age 50 or older and not up to date on
CRC screening. If the patients agreed to take the FOBT
cards home, the MA showed them how to use it and
answered basic questions about the test. If patients had
questions beyond the MA’s scope of practice, patients
were told to discuss this during the provider visit. The
provider also had a chance to reinforce the MA’s recom-
mendation to perform the test or to attempt to change
a patient’s decision if the patient did not agree to the
screening when the MA offered the test.
Improved access to diagnostic colonoscopy
Before August, 2009, uninsured EFHC patients had
access to diagnostic colonoscopies only through self-
pay, charity programs, or care at public hospitals.
Each of those modes has limitations. Most uninsured
EFHC patients would find the cost of self-financing a
colonoscopy not feasible. Charity care applications’
bureaucratic and documentation requirements can be
challenging for all patients, especially those with low
literacy. Furthermore, public hospitals in the Chicago
area tend to have long waitlists for services, especially
procedural tests like colonoscopy. These challenges
may have caused some providers to be unwilling to
use FOBT for CRC screening if they believed a
patient could not get a timely diagnostic colonoscopy
if the FOBT result was positive.
In August, 2009, EFHC and Northwestern Memorial
Hospital implemented an agreement to provide free diag-
nostic colonoscopies to uninsured patients who met
EFHC’s sliding scale fee criteria. Further eligibility re-
quirements included that the patient not be insulin-
dependent, be older than age 50 (or 40 if they have a
first-degree relative who had colorectal cancer), and have
some indicator for being high risk (i.e., have a positive
FOBT, first degree family member, history of rectal bleed-
ing, or tubular adenoma on prior colonoscopy). More
than just making colonoscopies affordable, the program
eased access by allowing EFHC to directly schedulepatients into dedicated appointment slots, thereby re-
ducing the scheduling complexity for the patient. Fur-
ther, pre-procedure preparation instructions and materials
were given at EFHC to reduce literacy barriers and increase
compliance. Patients for whom transportation was a bar-
rier were given the option of being chaperoned to and
from the appointment by an EFHC staff member.
Improvements in CRC screening rate
By October, 2009, the screening rate at EFHC had more
than doubled to 43%. Because the changes above were
implemented concurrently, it is not known which of these
system changes was most responsible for the increase in
the CRC screening rate. The multiple strategies employed
at EFHC and the relatively high rate of CRC screening
achieved by these interventions means that the “usual
care” group in this study is a strong comparator.
Methods
Study design and waiver of informed consent
This study is a randomized controlled clinical trial with
randomization at the level of either the patient or the
household (if two or more patients in the same household
were eligible for the study); the latter was done to ensure
that patients living in the same household would not be
randomized to different study arms, because the outreach
to one would likely effect the outcome of the other. This
study was approved by the Northwestern University In-
stitutional Review Board (IRB). It was approved with a
waiver of patient informed consent for randomization
because it met previously established criteria: 1) very low
risk to patients, as is typically the case for interventions
designed to improve adherence to national guidelines, 2)
informed consent could not be obtained without seriously
threatening the validity of the study (i.e., if we attempted
to obtain informed consent, patients in the usual care
arm would be made aware of their need for repeat CRC
screening), and 3) all patient information (e.g., demo-
graphic, diagnoses) and outcomes were obtained using
data collected during the routine course of their care by
querying the EHR database. We have used this same ap-
proach in prior comparative effectiveness studies, includ-
ing a previous trial of outreach to improve CRC screening
[14]. Conducting this study with a waiver of informed
consent allows for the entire population of eligible pa-
tients to be included in the study, thereby achieving a true
assessment of effectiveness without selection bias. After
IRB approval, this study was also approved by EHFC’s Re-
search Review Committee.
Inclusion and exclusion criteria
The eligibility criteria are shown in Table 1. The inclu-
sion criteria were age 51–74 years, preferred language
listed as English or Spanish, and an FOBT completed
Table 1 Criteria for identifying patients eligible for the study
Inclusion Criteria
Age 51-74 years at start of study
Language English or Spanish
FOBT done in year before study FOBT completed in year before study




Screening by another test Colonoscopy (CPT code 45.23) within 10 years
Flexible sigmoidoscopy (CPT code 45.24) within 5 years
Conditions that suggest FOBT screening may be
inappropriate
Chronic diarrhea (ICD-9 787.91)
Inflammatory bowel disease: Crohn’s (CPT code 555.xx) or Ulcerative Colitis (CPT code 556.xx)
Iron deficiency anemia (CPT code 280.9)
Gastrointestinal bleeding (CPT code 578.xx)
Colonic polyp (CPT code 211.3)
Malignant neoplasm of colon and other specified sites of colon and large intestine (ICD-9-CM
codes 153.X, 154.0, 154.1, 197.5, V10.05)
Conditions that make colorectal cancer screening
inappropriate
Total colectomy (CPT codes 44150–44153, 44155–44156, 44210–44212; ICD-9-CM codes 45.8)
Medications that may affect the decision to screen
or use FOBT
Clopidogrel, warfarin, or dabigatran
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6, 2012. We excluded patients with any of the following:
(1) colonoscopy within 10 years, (2) flexible sigmoidos-
copy within 5 years, (3) medical conditions suggesting
CRC screening through FOBT may be inappropriate,
including chronic diarrhea, inflammatory bowel disease,
iron deficiency, previous colonic polyp, use of medica-
tions in the previous 1 month that elevate the risk of a
false-positive FOBT (i.e., plavix or warfarin), and medical
conditions that make CRC screening inappropriate
(metastatic cancer or previous total colectomy).Identification of eligible patients and randomization
We used structured query language (SQL) to analyze
EFHC’s EHR data to identify eligible patients. The accur-
acy of the query was confirmed by reviewing 25 random
patients identified as being eligible and overdue and 25
identified as not being overdue. The query was also used
to obtain patients’ medical record numbers, demographics,
preferred language, number of chronic medical conditions,
number of visits to the clinic in the past 12 months,
primary care provider, and contact information.
To prevent having patients in the same household being
assigned to different groups, we first identified all eligible
patients who had the same address (28 patients, 14 house-
holds). We then used a random number generator to as-
sign households in the first half of the list to the
intervention (N = 7) and the remainder to the usual caregroup (N = 7). This process was repeated for all remaining
eligible patients (N = 422) with a unique address.
Conceptual framework
Most quality of care problems are due to a combination
of patient, provider, and system-level factors. Any one of
these may be rate-limiting so that care remains subopti-
mal even if most other aspects of care are done well. For
example, if the care team routinely recognizes when pa-
tients are due for CRC screening but the patient does not
understand why s/he needs to be screened or the instruc-
tions are intimidating, the test may not be performed. For
this study, we developed a conceptual framework of like-
ly barriers to optimal care and then designed the mul-
tifaceted intervention to address each of these barriers
(Table 2). We believe that the components of the inter-
vention may each have small, incremental effects that are
both additive and synergistic, although we will not be able
to determine the incremental effects of all individual com-
ponents (see analysis plan below).
Development of outreach tools
Letters, automated telephone calls, and texts
We developed simple, short messages to remind patients
they are due for screening. All calls, text, and print mate-
rials were developed in English and translated into Span-
ish. Bilingual staff worked to ensure equivalency of the
two language versions. EFHC’s EHR includes patients’
preferred language, and all messages are first sent in the
Table 2 Conceptual framework for the intervention components
Barrier Intervention component(s) to address barrier
No clinical systems in place to identify patients who need
repeat screening, unless they present for care
EHR query to identify patients due for repeat screening; outreach to patients
(half randomized to intervention)
No personal systems in place for patients to track when
preventive services are due
Automatic phone/text reminders to remind patients they are due for screening
Low adherence to repeat screening because of financial
and/or logistical barriers
Mail FOBT kits to patients
Patients forget to return FOBT Automatic phone/text reminders to patients who do not return FOBT within 2 weeks
Low priority and/or risk perception for CRC Call from CRC Screening Coordinator at 3 months to patients who do not complete
FOBT to explain need for screening
Change of phone number and/or address makes initial
reminders unsuccessful
When CRC Screening Coordinator calls at 3 months, he can use updated information
(i.e., from a recent visit)
Patients do not understand instructions Mailed FOBT kits include plain language information, instructions, and direct phone
number for CRC Screening Coordinator
Lack of understanding of polyps, CRC, and recommendation
for FOBT screening
Call from CRC Screening Coordinator at 3 months to patients who do not complete
FOBT to explain why they need repeat screening, answer questions, and mail another
FOBT if requested; letter from CRC Screening Coordinator when FOBT results are
negative to remind patients to repeat screening in 1–2 years and give due date
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also available in the other language from the CRC Screen-
ing Coordinator; this strategy will address problems if the
language preference recorded in the EHR is incorrect.
After initial versions were developed, we held a focus
group and had EFHC patients with Spanish listed as their
preferred language review, critique, and provide feedback
on all outreach materials. The final versions of the letter,
text message, and automated phone call message are
shown in the Additional file 1.
Development of fecal occult blood testing kit instructions
For this project, we are using the PolyMedco OC-Light
Fecal Occult Blood Test, an immunoassay that detects
human hemoglobin in feces [15]. This class of screening
test is referred to as fecal immunochemical tests (FIT).
It can detect hemoglobin in concentrations as low as
0.05 micrograms/mL. It does not cross-react with animal
hemoglobin from consumed meat, and it does not cross-
react with vegetables containing peroxidase (e.g., horse-
radish, cauliflower, broccoli) or toilet bowl cleaners. The
reported sensitivity and specificity of the OC Light for
detecting CRC are 91.0% and 93.8% [16], which is con-
sistent with the reported range for other FIT tests [1]. It
is a single-sample test, which decreases the demand on
patients and increases adherence compared to guaiac
cards that require multiple samples [17-20]. This FIT
test was used for both the intervention and usual care
groups; all EFHC clinics were stocked with the FIT test
and staff was trained in the use of this test so it became
the standard of care for CRC screening.
The manufacturer’s instructions for the test were not
designed for a patient population with low literacy. Wetherefore undertook a comprehensive redesign of the in-
structions, including identification of each key step, de-
velopment of short instructions for each step, and
creation of graphics to clarify and reinforce the text. The
instructions were first reviewed by a focus group of
EFHC staff. After revisions, we conducted a focus group
and asked patients to simulate using the test and follow
the instructions without any additional preparatory in-
formation. Multiple revisions were made in response to
patient and staff suggestions and incorporated into final
version of instructions. The English and Spanish versions
of FIT instructions are shown in the Additional file 1.Two-phase intervention
Initial intervention
We group patients into weekly cohorts based on the date
of their eligible FOBT between March 2011 and March
2012. Every Monday, all patients due for repeat FOBT
screening in the coming week have a FIT kit mailed to
their home, along with a letter from their primary care
provider and the FIT instructions. We then send the au-
tomated phone call and two days later a text message via
the commercial system (CallPointe; Tuscon, AZ) that
EFHC uses routinely for patient reminders and health
promotion messages. The system software allows us to
track the number of completed phone and text messages,
and whether the phone message is answered by a person
or a machine.
Two weeks after the initial reminders and FIT kit mail-
ing, we query the EHR to identify patients who did not
return the mailed kit. Those who do not return the kit re-
ceive another automated phone call and text message.
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months
Three months after the initial outreach and FIT kit mail-
ing, we again query the EHR to identify patients in the
intervention group who have not completed screening;
the CRC Screening Coordinator then attempts to contact
them by phone. We chose this three month cutoff because
in previous studies it took 3–4 months to see the full ef-
fect of an initial outreach intervention [14,21]. By waiting
three months until we can see the full effect of the initial
intervention, we should be able to estimate the incremental
effectiveness of the CRC Screening Coordinator calls be-
yond the effects of the initial outreach. In addition, by
waiting three months to make personal calls, we may be
able to contact patients who have changed phones or ad-
dresses but who had a clinical encounter during this
period and now have updated information in the EHR. If
the CRC Screening Coordinator is able to speak with the
patient, he explains why repeat testing is needed, answers
questions, and explores barriers to completing the FIT. If
the patient verbalizes willingness to complete the test,
another FIT kit is mailed to them. Persuasion theory
suggests that obtaining verbal commitment will increase
the proportion of patients who will actually complete the
test [22,23]. If the CRC Screening Coordinator only
obtains voicemail, a standard script is read reviewing key
points and leaving a direct telephone number for contact.Education tools for patients after FIT testing
Follow-up of negative screening tests
FIT kits are processed by the EFHC laboratory and results
entered into their EHR. FIT results are sent to the CRC
Screening Coordinator. If the FIT is negative, the Coord-
inator notifies the patient by mail; the letter (Additional
file 1) includes a reminder that the test must be repeated
in one year along with a reminder card. Our goal is to
prime patients for the second round of reminders/mail-
ings they will receive in one year and to encourage them
to initiate contact on their own. This priming may be im-
portant because many patients may change phone num-
bers, addresses, or providers over the course of a year.Follow-up of positive screening tests
Nationally, a high proportion of patients with a positive
FOBT do not complete a diagnostic evaluation [24-32].
To address this, if the FIT is positive (i.e., blood detected),
the CRC Screening Coordinator works with the patient’s
physician to arrange follow-up colonoscopy. Patients are
tracked and reminded until this is completed or until the
patient refuses. The date of completed colonoscopy, find-
ings, pathology results, and recommended date for repeat
screening (if completely normal) or surveillance (if abnor-
mal) are added to the patient’s problem list in the EHR.During the first few months of the project, we learned
that patients often struggled to understand the colonos-
copy preparation instructions, which had high literacy and
cognitive demands. This is consistent with previous re-
search showing that colonoscopy preparation is subopti-
mal, which decreases the sensitivity of the test for finding
polyps and may even require repeat colonoscopy [33,34].
Therefore, we applied the same methods described above
for developing the FIT instructions to create simplified
colonoscopy preparation instructions (see Additional file
1). We are also working to develop a video that explains to
patients what a colonoscopy is and how it is performed to
ease their concerns and maximize completion rates. Pre-
vious studies have reported that only 25-59% of patients
with positive FOBTs undergo diagnostic colonoscopy
[24,25,27-31,35-38]. Although our study was not designed
to test whether the tools we developed will improve com-
pletion rates, we hope that this may be possible in future
studies.
Outcome assessment
The primary outcome for the study is completion of a
FOBT within six months of the date when a patient first
became due for repeat screening (i.e., one year after their
qualifying FOBT). The outcome is assessed by querying
the EHR for both intervention and usual care patients to
determine if a FOBT screening test was completed. By
relying only on the EHR for outcome assessment for
both the intervention and usual care group, we hope to
avoid any bias that might occur in the rates of detection
of FOBT completion. Specifically, if the CRC Screening
Coordinator was aware that a FIT was performed but
the results were not documented in the EHR, the patient
would still be classified as having not completed screen-
ing. Using only EHR data for outcome assessment is
conceptually similar to blinded outcome assessment.
We have found that some patients randomized to the
intervention have a repeat FOBT done at a clinical en-
counter shortly before the date that they are due for the
intervention. The intervention is not conducted for these
patients. Equal numbers of patients in the control group
are expected to complete repeat testing prior to their
due date, but we remain blinded to the outcomes in the
control group. Because these patients were randomized
prior to knowing their outcomes, we will include them
in the main analyses.
Power calculation
The repeat screening rate for patients at EFHC was
not known at the time this study was designed because
many eligible patients had only recently completed their
first FOBT. We assumed that 35% of patients in the
usual care group will achieve the primary outcome, simi-
lar to the rate in previously published studies. To detect
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alpha = .05), we would need 752 patients (376 in each
arm). This is less than the 800 patients that we estimated
will be eligible for the study. We think intervention ef-
fects less than 10% are not important to detect because
it would not be substantial enough to justify the efforts
required to implement this type of an intervention in
CHCs.
Analytic plan
The rate of FOBT completion for the intervention and
usual care groups will be analyzed with an intention to
treat approach that includes all patients randomized; this
will provide a true picture of the effectiveness of the
intervention that will allow other health care providers
(especially similar CHCs) to know the probable benefits
of implementing this intervention across their health
care center or system.
In addition, we will conduct a subgroup analysis strati-
fied by the number of visits to the clinic during the follow
up period to see if the intervention’s main benefit is to ob-
tain CRC screening for patients with infrequent clinic
visits. We will also examine the fidelity of the interven-
tion, including the proportion of patients who did not re-
ceive the mailed FIT kit (i.e., returned to sender because
of incorrect address), the proportion who had the text
message completed, the proportion that had the auto-
mated call completed, and the proportion of automated
calls answered a) in person or b) by an answering ma-
chine. We will conduct logistic regression to analyze the
association between the components of the intervention
that were received (both the number and type) and the
likelihood of FIT completion. We will also assess the in-
cremental value of the three-month outreach calls by the
CRC Screening Coordinator.
Discussion
This study will determine whether a multifaceted inter-
vention is able to improve rates of repeat FOBT for CRC
screening compared to usual care. It is important to stress
that “usual care” at EFHC is at a high standard, consisting
of team-based care for promoting CRC screening, point-
of-care alerts for clinicians, and performance measure-
ment and feedback to providers. These efforts to improve
CRC screening are probably far greater than those in
most private practices and CHCs. Health services re-
search studies sometimes have relatively weak “usual care”
groups; although the care for the control group may be
“typical” care, it is not consistent with what the literature
has shown to be evidence-based best practice. Thus, it
can be hard to determine whether a new intervention
truly has a marginal value beyond what has already been
shown to be beneficial. In contrast, the usual care group
in this study includes multiple evidence-based strategiesto improve preventive service delivery through point-of
-care quality improvement methods.
This study will examine use of an EHR system for
population-based disease management and outreach among
vulnerable patients cared for in CHCs. Very few studies
have examined the benefit of using EHR-based interven-
tions in this setting. These data are important, as more
CHCs are seeking to become patient-centered medical
homes with good health information technology (HIT) in-
frastructure. In addition, our study design will allow us to
separate the effects of low cost technology (automated
reminders) followed by more costly efforts (telephone
outreach by a CRC Screening Coordinator). This tiered
outreach strategy could help clinics maximize efficiency
and make decisions as to when it is helpful to use more
resource intensive strategies.
Although the main goal of this study is to determine
the comparative effectiveness of the intervention com-
pared to usual care, we also want to see if it is possible
to achieve the high rates of adherence to CRC screening
with annual FOBT that are necessary to achieve measur-
able reductions in CRC mortality. Few studies have ex-
amined the rate of repeat FOBT testing [11,12,39], and
to our knowledge none have been conducted in popu-
lations with a high prevalence of barriers to screening
(e.g., low literacy, varied cultural norms, transportation
difficulties). A study from the Department of Veterans’
Affairs found that only 42% of men received adequate
screening (FOBTs in at least 4 out of 5 years) [12]. A
study of managed care plan enrollees in Washington
state found that only 44% completed repeat screening
within 2 years [11]. The assumption that FOBT is an ef-
fective CRC screening strategy presumes it will be done
at least biennially, and cost-effectiveness studies of CRC
screening strategies have found that the results are sensi-
tive to the rate of adherence [13]. Our study will provide
critical information for providers and policymakers as
they consider different strategies (i.e., FOBT, flexible sig-
moidoscopy, colonoscopy) to increase CRC screening
among vulnerable populations.
If effective, the study intervention will serve as a model
for CHCs of how to improve rates of repeat FOBT among
vulnerable populations. Our intervention relies on tech-
nology that is increasingly available and declining in
cost, including EHR systems, automated phone and text
messaging, and FITs for CRC screening. This approach
was taken to try to ensure generalizability and allow us to
rapidly disseminate the intervention through networks of
CHCs.
Conversely, if the intervention is not effective or if
rates are suboptimal despite the intervention, our find-
ings will spur future research and policy analyses about
alternative screening strategies to address disparities.
Endoscopy is more sensitive than FOBT for CRC
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ever, the costs of endoscopy are higher and many
CHCs have limited access to endoscopy. Although
there are significant barriers to using endoscopy for
CRC screening, previous studies have shown that
nurses can be trained to do flexible sigmoidoscopy ef-
fectively and safely [40-43]. Endoscopy is an acceptable
screening strategy among populations with CRC screen-
ing disparities [44-50]. A study of screening colonoscopy
for patients in East Harlem (55% Hispanic, 33% African
American) found that 66% of patients completed colonos-
copy with the aid of a patient navigator [51]. In addition,
other studies have found that many patients cared for in
safety net settings would prefer endoscopy to FOBT
[47,50,52]. Such screening alternatives may need in-
creased scrutiny should our intervention fail to achieve
high rates of annual screening.
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